Nevertheless, individual patient factors, including the presence of other autoimmune conditions, cardiovascular risk factors, and previous tolerance of weight loss interventions, should inform the prescribing decision
Regulatory environment (external): Active uncertainty - FDA's April 2026 proposal to restrict 503B compounding remains open for public comment through June 29, 2026
Material can appear clean by conventional chromatography while still containing sequence variants, deamidation, oxidation, acylation variants or other subtle modifications that could affect potency, stability and potentially immunogenicity
Check for visible changes: cloudiness, particles, or unusual discoloration
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio